1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics 2020 - European Union

Cancer Analysis & Statistics 2020 - European Union

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Datamonitor Healthcare

All regions

1-30 of 62 reports

NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

  • $ 22000
  • April 2018
  • 196 pages

Mantle cell lymphoma (MCL) is a rare form of B-cell non-Hodgkin’s lymphoma (NHL), accounting for 3–6% of new NHL cases. The term MCL derives from the growth pattern of the lymphoma, with tumor cells ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

NHL: Follicular Lymphoma Forecast and Market Analysis to 2025

  • $ 22000
  • April 2018
  • 229 pages

Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts for more than 20% of ...

  • Cancer
  • Lymphoma
  • European Union
  • Japan
  • United States

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034

  • $ 22000
  • April 2018
  • 162 pages

Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third ...

  • Cancer
  • Lymphoma
  • European Union
  • Japan
  • United States

Ovarian Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • March 2018
  • 159 pages

Ovarian cancer medicines have traditionally been subject to low restrictions, as most patients usually start and remain on inexpensive platinum-based therapies. However, beginning with the launch of vascula ...

  • Cancer
  • Ovarian Cancer
  • Therapy
  • European Union
  • United States

Drug Overview: Rubraca

  • $ 10000
  • January 2018
  • 29 pages

Drug Overview Rubraca (rucaparib) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations ...

  • Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • European Union
  • Market Description

Drug Overview: ipatasertib

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview  Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt. Akt is dysregulated in a number of malignancies through ...

  • Cancer
  • Pathology
  • Prostate Cancer
  • European Union
  • Japan

Drug Overview: apalutamide

  • $ 10000
  • January 2018
  • 18 pages

Drug Overview  Apalutamide (Johnson&Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) ...

  • Cancer
  • Pathology
  • Prostate Cancer
  • European Union
  • United States

Drug Overview: darolutamide

  • $ 10000
  • January 2018
  • 17 pages

Drug Overview  Darolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens ...

  • Cancer
  • Hormone
  • Prostate Cancer
  • Therapy
  • European Union

Drug Overview: DCVAC/PCa

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview DCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Cancer
  • Cell Therapy
  • Medical Biotechnology
  • Prostate Cancer
  • European Union

Drug Overview: Zytiga

  • $ 10000
  • January 2018
  • 21 pages

Drug Overview Zytiga (abiraterone acetate; Johnson&Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates ...

  • Cancer
  • Hormone
  • Therapy
  • European Union
  • Supply

Drug Overview: Xtandi

  • $ 10000
  • January 2018
  • 19 pages

Drug Overview Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits ...

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug Overview: Xofigo

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased ...

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug Overview: Tecentriq

  • $ 10000
  • January 2018
  • 82 pages

Drug Overview Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • United States

Drug Overview: Masitinib

  • $ 10000
  • January 2018
  • 45 pages

Drug Overview Masitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor recepto ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • Prostate Cancer
  • European Union

Drug Overview: Jevtana

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) ...

  • Cancer
  • Prostate Cancer
  • Therapy
  • European Union
  • Japan

Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024

  • $ 22000
  • January 2018
  • 699 pages

DISEASE OVERVIEW Prostate cancer is a hormonally fueled disease, and the most common form of cancer found in males. Consequently, there is a high incentive for drug development in this indication due to ...

  • Cancer
  • Prostate Cancer
  • European Union
  • United States
  • Demand

Drug Analysis: Rubraca

  • $ 10000
  • January 2018
  • 29 pages

Drug Overview Rubraca (rucaparib) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations ...

  • Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • European Union
  • United States

Drug Analysis: ipatasertib

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt. Akt is dysregulated in a number of malignancies through loss ...

  • Cancer
  • Pathology
  • Prostate Cancer
  • European Union
  • Japan

Drug Analysis: apalutamide

  • $ 10000
  • January 2018
  • 18 pages

Drug Overview Apalutamide (Johnson and Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently ...

  • Cancer
  • Pathology
  • Prostate Cancer
  • European Union
  • United States

Drug Analysis: darolutamide

  • $ 10000
  • January 2018
  • 17 pages

Drug Overview Darolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens ...

  • Cancer
  • Hormone
  • Prostate Cancer
  • Therapy
  • European Union

Drug Analysis: DCVAC/PCa

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview DCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Cancer
  • Cell Therapy
  • Medical Biotechnology
  • Prostate Cancer
  • European Union

Drug Analysis: Zytiga

  • $ 10000
  • January 2018
  • 21 pages

Drug Overview Zytiga (abiraterone acetate; Johnson and Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates ...

  • Cancer
  • Hormone
  • Therapy
  • European Union
  • Supply

Drug Analysis: Xtandi

  • $ 10000
  • January 2018
  • 19 pages

Drug Overview Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits ...

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug Analysis: Xofigo

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of ...

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug Analysis: Tecentriq

  • $ 10000
  • January 2018
  • 82 pages

Drug Overview Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • United States

Drug Analysis: Masitinib

  • $ 10000
  • January 2018
  • 45 pages

Drug Overview Masitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor recepto ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • Prostate Cancer
  • European Union

Drug Analysis: Jevtana

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) ...

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug analysis: Cotellic

  • $ 10000
  • December 2017
  • 26 pages

Drug Overview Cotellic (cobimetinib; Exelixis/Roche) is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • United States

Drug analysis: Binimetinibi

  • $ 10000
  • December 2017
  • 27 pages

Drug Overview Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK ...

  • Cancer
  • Monoclonal Antibody
  • European Union
  • United States
  • Supply

Drug analysis: Erbitux

  • $ 10000
  • December 2017
  • 34 pages

Drug Overview Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR). The ...

  • Cancer
  • Medical Biotechnology
  • Therapy
  • European Union
  • Supply

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on